123 related articles for article (PubMed ID: 12669244)
41. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
42. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
43. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
[TBL] [Abstract][Full Text] [Related]
45. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
[TBL] [Abstract][Full Text] [Related]
46. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E
J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118
[TBL] [Abstract][Full Text] [Related]
47. Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization.
Lawendowski CA; Giurleo GM; Huang YY; Franklin GJ; Kaplan JM; Roberts BL; Nicolette CA
J Immunol; 2002 Sep; 169(5):2414-21. PubMed ID: 12193709
[TBL] [Abstract][Full Text] [Related]
48. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
Oved K; Lev A; Noy R; Segal D; Reiter Y
Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
50. Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2.
Myers CE; Dionne SO; Shakalya K; Mahadevan D; Smith MH; Lake DF
Hum Immunol; 2008 Jan; 69(1):24-31. PubMed ID: 18295672
[TBL] [Abstract][Full Text] [Related]
51. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
[TBL] [Abstract][Full Text] [Related]
52. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
53. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
54. Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes.
Dionne SO; Smith MH; Marincola FM; Lake DF
Cell Immunol; 2001 Dec; 214(2):139-44. PubMed ID: 12088412
[TBL] [Abstract][Full Text] [Related]
55. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
Lev A; Novak H; Segal D; Reiter Y
J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
[TBL] [Abstract][Full Text] [Related]
56. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
57. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
58. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
59. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
[TBL] [Abstract][Full Text] [Related]
60. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
